As we move away from a system of external development grants that help us maintain our HIV models to a system where our returns on investment support the work that we do, there’s a concern that there will be some slimming down of services that get patients in to our practice, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
As we move away from a system of external development grants that help us maintain our HIV models to a system where our returns on investment support the work that we do, there’s a concern that there will be some slimming down of services that get patients in to our practice, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
Transcript
What are the biggest management challenges that we’re still facing when trying to treat patients with HIV?
HIV has made a tremendous amount of progress from being a disease that was a death sentence and hugely stigmatized to now being something that people manage like a chronic illness like diabetes. But I think one of the biggest management problems that we face is that the HIV care models that we use are based on a lot of funding. We’ve had a lot of philanthropic funding that supports the care models For example, in my practice, I have a massage therapist that takes care of my patients because we got a grant that allows that.
As we move away from a system of external development grants kind of helping us maintain our HIV models to a system where our [ROIs] returns on investment support the work that we do, there’s a concern that there will be some slimming down of those services and those services are actually some of the things that help bring patients into our practices. We know with population health and value-based care delivery that it’s all about getting your patients to come in. In HIV, because of the stigma and all of the other issues, we work really hard on getting our patients to come in, and one of the ways we do that is through nontraditional services like massage therapy, reiki, etc. So, our big management question is going to be what happens to our ability to continue that work when the financial models behind that change going down the line.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More